These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 25634751

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Validation of the pretreatment neutrophil-lymphocyte ratio as a predictor of overall survival in a cohort of patients with pancreatic ductal adenocarcinoma.
    Ben Q, An W, Wang L, Wang W, Yu L, Yuan Y.
    Pancreas; 2015 Apr; 44(3):471-7. PubMed ID: 25423560
    [Abstract] [Full Text] [Related]

  • 23. Paraneoplastic Ma Antigen-Like 1 as a Potential Prognostic Biomarker in Human Pancreatic Ductal Adenocarcinoma.
    Kuwae Y, Kakehashi A, Wakasa K, Wei M, Yamano S, Ishii N, Ohsawa M, Wanibuchi H.
    Pancreas; 2015 Jan; 44(1):106-15. PubMed ID: 25251443
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Ataxia-telangiectasia-mutated protein kinase levels stratify patients with pancreatic adenocarcinoma into prognostic subgroups with loss being a strong indicator of poor survival.
    Kamphues C, Bova R, Bahra M, Klauschen F, Muckenhuber A, Sinn BV, Warth A, Goeppert B, Endris V, Neuhaus P, Weichert W, Stenzinger A.
    Pancreas; 2015 Mar; 44(2):296-301. PubMed ID: 25423555
    [Abstract] [Full Text] [Related]

  • 26. Metastatic lymph node ratio as an important prognostic factor in pancreatic ductal adenocarcinoma.
    Robinson SM, Rahman A, Haugk B, French JJ, Manas DM, Jaques BC, Charnley RM, White SA.
    Eur J Surg Oncol; 2012 Apr; 38(4):333-9. PubMed ID: 22317758
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Reproducibility of tumor budding assessment in pancreatic cancer based on a multicenter interobserver study.
    Karamitopoulou E, Esposito I, Zlobec I, Insilla AC, Wartenberg M, Schaeffer DF, Kalloger S, La Rosa S, Sempoux C, Ramos Centeno I, Lohneis P.
    Virchows Arch; 2021 Apr; 478(4):719-726. PubMed ID: 33330964
    [Abstract] [Full Text] [Related]

  • 29. Absence of FLICE-inhibitory protein is a novel independent prognostic marker for very short survival in pancreatic ductal adenocarcinoma.
    Schmid SJ, Glatzel MC, Welke C, Kornmann M, Kleger A, Barth TF, Fulda S, Lennerz JK, Möller P.
    Pancreas; 2013 Oct; 42(7):1114-9. PubMed ID: 24005232
    [Abstract] [Full Text] [Related]

  • 30. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer.
    Wang LM, Kevans D, Mulcahy H, O'Sullivan J, Fennelly D, Hyland J, O'Donoghue D, Sheahan K.
    Am J Surg Pathol; 2009 Jan; 33(1):134-41. PubMed ID: 18971777
    [Abstract] [Full Text] [Related]

  • 31. Loss of Raf-1 kinase inhibitory protein in pancreatic ductal adenocarcinoma.
    Kim HS, Kim GY, Lim SJ, Kim YW.
    Pathology; 2010 Dec; 42(7):655-60. PubMed ID: 21080875
    [Abstract] [Full Text] [Related]

  • 32. Clinico-pathological characteristics and clinical outcome of different histological types of pancreatic cancer in a large Middle European series.
    Stotz M, Eisner F, Szkandera J, Absenger G, Kornprat P, Lackner C, Samonigg H, Gerger A, Pichler M.
    J Clin Pathol; 2013 Sep; 66(9):753-7. PubMed ID: 23750038
    [Abstract] [Full Text] [Related]

  • 33. Prognostic significance of immunohistochemical RhoA expression on survival in pancreatic ductal adenocarcinoma: a high-throughput analysis.
    Dittert DD, Kielisch C, Alldinger I, Zietz C, Meyer W, Dobrowolski F, Saeger HD, Baretton GB.
    Hum Pathol; 2008 Jul; 39(7):1002-10. PubMed ID: 18495213
    [Abstract] [Full Text] [Related]

  • 34. Can statistically determined prognostic factors predict the long-term survival of patients with pancreatic ductal adenocarcinoma following surgical resection?: Clinicopathological analysis of 82 long-term survivors.
    Shin SH, Kim SC, Hong SM, Song KB, Lee JH, Park KM, Lee YJ.
    Pancreas; 2014 May; 43(4):571-7. PubMed ID: 24681875
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Presence of primary cilia in cancer cells correlates with prognosis of pancreatic ductal adenocarcinoma.
    Emoto K, Masugi Y, Yamazaki K, Effendi K, Tsujikawa H, Tanabe M, Kitagawa Y, Sakamoto M.
    Hum Pathol; 2014 Apr; 45(4):817-25. PubMed ID: 24656092
    [Abstract] [Full Text] [Related]

  • 37. Clinicopathologic features and prognostic implications of MYBL2 protein expression in pancreatic ductal adenocarcinoma.
    Yu R, Li C, Lin X, Chen Q, Li J, Song L, Lin L, Liu J, Zhang Y, Kong W, Ouyang X, Chen X.
    Pathol Res Pract; 2017 Aug; 213(8):964-968. PubMed ID: 28559119
    [Abstract] [Full Text] [Related]

  • 38. Preoperative cognitive function predicts survival in patients with resectable pancreatic ductal adenocarcinoma.
    Baekelandt BM, Hjermstad MJ, Nordby T, Fagerland MW, Kure EH, Heiberg T, Buanes T, Labori KJ.
    HPB (Oxford); 2016 Mar; 18(3):247-54. PubMed ID: 27017164
    [Abstract] [Full Text] [Related]

  • 39. Association of microRNA-21 expression with its targets, PDCD4 and TIMP3, in pancreatic ductal adenocarcinoma.
    Nagao Y, Hisaoka M, Matsuyama A, Kanemitsu S, Hamada T, Fukuyama T, Nakano R, Uchiyama A, Kawamoto M, Yamaguchi K, Hashimoto H.
    Mod Pathol; 2012 Jan; 25(1):112-21. PubMed ID: 21983937
    [Abstract] [Full Text] [Related]

  • 40. CD40 expression in pancreatic cancer.
    Unek T, Unek IT, Agalar AA, Sagol O, Ellidokuz H, Ertener O, Oztop I, Karademir S, Yilmaz U, Astarcioglu I.
    Hepatogastroenterology; 2013 Jan; 60(128):2085-93. PubMed ID: 24719952
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.